Contacts: The Erganoid-1™ Swis Sw iss Medic ical al Unio ion SA CH-550.1.183.498-2 Improving cancer treatments c/o Y-Parc SA Rue Galilée 7 - 1400 Yverdon-les-Bains Daniil Golubev (CEO) 24 October 2019 To the attention of the Marion Argi (CMO) Ju Jury members of of t the S e Swiss ss In Innovation on C Challen enge ge Emanuele Pizzatti (CFO) Table of contents Ta What is Swiss Medical Union 2 InnoSuisse Project – Swiss Innovation Agency 16 The Problems 3 Organizational Plan – Key Companies 17 The ineffective traditional approach 4 Joint-venture – Optimal scenario 18 The criticality of the time to prognosis & treatment 5 Achievements to date 19 Impacts on the healthcare sector 6 Go To Market – Strategic elements 20 The Solution: Erganoid - 1 ™ 7 Go To Market – Sales orientation 21 Three «Organs» for the «Man-on-the-chip» 8 Use of funds: key elements & deal info 22 The «Man-on-the-chip»: the magic 9 Financials: Expected results and EV 23 Swiss Medical Union approach: USP summary 10 Annex I: Bibliography 24 Business model: clinical practice inclusion and R&D Labs 11 Annex II: Exit strategy 25 The market: definitions 12 Annex III: Exit strategy, strategic acquisition 26 The market: data & sales orientation 13 Annex IV: Considerations at scale: Key Financial & strategic 27 Competitive landscape: by USP 14 metrics Our Team, business advisors and partners 15
What is Swiss Medical Union’s Erganoid noid is a medical device - Micro-Bioreactor - able to provide qui The Er Ergano quick (7 days) and per performi ming ng ex ex-vi vivo vo tests on human cells to support medics and practitioners in clinical decisions in cancer treatment prescription. It is as an effective and reliable mean for significantly re reducing th the ti time to to tre treatm tment t and th the incidence of negati tive side effects ts of unnecessary disease complications and palliative treatments while decreasing considerably the overall healthcare spending in an impactful way. Specifically, from the academic researches and initial tests, the Er Ergano noid is expected to be extraordinarily performing in terms of human ce cells survival rate on a ch chip as a testing bio-environment (70% and potentially 95% with the V.2) and su success ss of tre reatment pre rediction opposing the current slow and ineffective comparable solutions available on the market where only 40% of the cells are able to survive on the chip and not satisfying results are given in more than two month. Without Prejudice & Confidential 2
The Problems The effectiveness of cancer treatment depends on many factors, such as the time gap between diagnosis and start of type of treatment treatment. These data are collected by all registries. The effectiveness of treatment also depends on the ty as well as the multidisciplinary care of the patient; the impact of which is more difficult to quantify (1) Three i Th interconnected m major p problems Ne Negative si side ef effects & & co complica cations In Increa easi sing co costs on on th the he healthc hcare Ti Time to treatment Palliative (comfort) treatments such as sec sector or Slow process and waiting time radiotherapy and generalized solutions as Costs raises with tr trial & error approach negatively impacts the su success r ess rate e of part primary cancer treatments are often not only leads to invasive – sometimes cations arises. the treatments as co complica used to gain time before the right cure not needed surgery - and non effective Early stage disease are likely to have has been prescribed. therapies but weight on the healthcare survival that is longer than ‘average’, Unprecise diagnostics leads then to expenditures and other ne ex negative whereas patients with advanced disease wrong t wr trea eatmen ents and then to perverse externalities. ex are likely to have survival that is shorter effects. than ‘average’. Moreover, it costs LIVES as cancer survival rate is 50% (2) 3 Without Prejudice & Confidential
The ineffective traditional approach USP 1: PROBLEM Complications of the current diagnostic & treatment approach The management of symptoms related to Mostly still ineffective and not time and cost efficient Post-treatments & side effects cancer and its treatment is an important part of cancer care, affecting the In the early 1970’s the median survival time Traditional & wrong treatments leads to side-effects § completion of treatment and quality of after diagnosis was one year, by 2007 it was life, as well as physical and psycho- logical six years and by 2011 it was ten years. Palliative measures are used to increase life expectancy – § functioning . . Sid Side effects may occur during However, most of the times there is not a is it ethical? Can we do more? active treatment, or months or even years complete resolution and patients still need to get further treatments. later. The most common side effects are No individualized approach § pain, fatigue, and emotional distress. Tr Traditional approach Succe ccess/Failure of + Chemotherapy ( often Ch 1 Tr Trial & error testing 3 + tr treatm tment t paired with other treatments) First diagnosis included bi biopsy is a medical No other No test commonly performed by Testing on “mice ce” Last st reso sorts s Patient Pa alt alternat ativ ives hosp spitalization a surgeon, interventional radiologist, or High risk sk & infect ctiveness As the patient § Applying treatment § Restart/finish the § 2-3 rounds of an interventional cardiologist involving arrives an initial protocols on a human process with a chimo-therapy are Patient disease extraction of sample cells or tissues for Biopsy test being by injecting a drug possibility of necessary before complications as the suggests an area of without full knowledge complications or death observing effects right treatment has examination to determine the presence or tissue in the body of consequence for non-respondents. (2-3 months). not been applied in isn't normal. extent of a disease. The tissue is generally due time. i. There is a 50% § Invasive treatments. § Complication risks chance the protocol examined unde under a mi micr croscope by by Secondary and lies on the is not going to work adverse effects of diagnosis. a pa patho hologist , and can also be analyzed ii. A patient could multiple treatments. have secondary 2 chemically. effects 4 Without Prejudice & Confidential
The criticality of the time to prognosis & treatment USP 2: PROBLEM Among the most used protocols (4) La Lack of of in indiv ivid idual al Tr Treatments as as Surgery to remove the tumour • Protocol 1 § current individual tests are Radiotherapy • Protocol 2 § performed via fe few Chemotherapy selected and pre- § • Protocol 3 approved protocols • …. Despite a net increase of 20% on average of survival rate, Chemotherapy is currently chosen for cancer patients on Tr Trial & Error basis, without certainty that the co correct treatment is choose. Drug testing via An Animal studies to predict value to human effect is difficult, studies take time and are ex expensive . Current prognosis, diagnosis and treatment processes Early diagnostic: typical waiting time is two weeks Prognosis delays , lab delays , treatment waiting time leads to Early diagnosis as spotting cancer early is important for improving survival, so it is important that patients with potential cancer symptoms are referred promptly. irreversible complications Receipt of first treatment following decision: typical waiting time is one month Sometimes it can take a while to get back lab results. This can be even The speed at which patients receive their first treatment can have a positive outcome on their harder to deal with when you’re waiting to get test results to see if it’s clinical outcome, so it is important that patients with cancer symptoms are treated promptly. cancer or if cancer has come back. It’s scary to find out about a change in blood counts, or a tumor or mass (lump) and not know if it’s cancer. Waiting for these results can be a frightening time, and people can go Receipt of first treatment following referral: typical waiting time is 2+ months through some strong emotions, including disbelief, anxiety, fear, anger, The speed at which patients receive their first treatment can have a positive outcome on their and sadness (5) clinical outcome, so it is important that patients with cancer symptoms are treated promptly. 5 Without Prejudice & Confidential
Recommend
More recommend
